Investor Relations | Financial Information
Capex, Depeciation, R&D
| U.S. GAAP | IFRS | ||||
|---|---|---|---|---|---|
| Unit:Yen millions / Fiscal Year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
| Investment in facilities Share of cash flow (%) | 173,592 91.9 |
173,429 94.9 |
212,355 96.7 |
291,337 94.5 |
275,709 86.0 |
| Depreciation expenses Share of net sales (%) | 106,631 7.7 |
124,984 9.2 |
140,285 9.5 |
177,031 9.3 |
206,285 9.5 |
| Cash flow (Net profit attributable to owners of parent + Depreciation expenses) | 188,836 | 182,764 | 219,625 | 308,329 | 320,472 |
| Research and development expenses Share of net sales (%) | 115,155 8.3 |
117,489 8.6 |
127,046 8.6 |
165,250 8.7 |
179,467 8.2 |
